Cadrenal Therapeutics, Inc.
CVKD
$12.32
-$0.1618-1.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.82% | -17.73% | |||
| Depreciation & Amortization | -92.73% | 1,275.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.93% | -8.19% | |||
| Operating Income | 4.93% | 8.19% | |||
| Income Before Tax | 4.63% | 8.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.63% | 8.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.63% | 8.17% | |||
| EBIT | 4.93% | 8.19% | |||
| EBITDA | 4.81% | 8.31% | |||
| EPS Basic | 10.35% | 18.34% | |||
| Normalized Basic EPS | 10.35% | 18.34% | |||
| EPS Diluted | 10.35% | 18.34% | |||
| Normalized Diluted EPS | 10.35% | 18.34% | |||
| Average Basic Shares Outstanding | 6.37% | 12.47% | |||
| Average Diluted Shares Outstanding | 6.37% | 12.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||